The spinal cord contains more than 20 distinct subclasses of neurons that form well-organized neural circuits capable of sensing the environment and generating motor behavior. Although recent studies have described the efficient in vitro generation of spinal motor neurons, the induction of the spinal cord as a whole tissue has not been achieved. In the present study, we demonstrate three-dimensional (3D) induction of dorsal spinal cord-like tissues from human pluripotent stem cells. Our 3D spinal cord induction (3-DiSC) condition recapitulates patterning of the developing dorsal spinal cord and enables the generation of four types of dorsal interneuron marker-positive cell populations. By activating Shh signaling, intermediate and ventral spinal cord-like tissues are successfully induced. After dissociation of these tissues, somatosensory neurons and spinal motor neurons are detected and express neurotransmitters in an in vivo manner. Our approach provides a useful experimental tool for the analysis of human spinal cord development and will contribute to research on the formation and organization of the spinal cord, and its application to regenerative medicine.
In 2008, researchers created human three-dimensional neural tissue – known as the pioneering work of “brain organoids.” In recent years, some researchers have transplanted human brain organoids into animal brains for applicational purposes. With these experiments have come many ethical concerns. It is thus an urgent task to clarify what is ethically permissible and impermissible in brain organoid research. This paper seeks (1) to sort out the ethical issues related to brain organoid research and application and (2) to propose future directions for additional ethical consideration and policy debates in the field. Toward (1), this paper first outlines the current state of brain organoid research, and then briefly responds to previously raised related ethical concerns. Looking next at anticipated scientific developments in brain organoid research, we will discuss (i) ethical issues related to in vitro brain organoids, (ii) ethical issues raised when brain organoids form complexes or have relationships with other entities, and (iii) ethical issues of research ethics and governance. Finally, in pursuit of (2), we propose research policies that are mindful of the ethics of brain organoid research and application and also suggest the need for an international framework for research and application of brain organoids.
Developmental timescales vary widely across species, with mammalian cortical neurogenesis ranging from just days to several months. Given the conserved laminar architecture and regulatory gene expression sequences, the underlying molecular mechanisms controlling neurogenesis rate remain unknown. Using mouse, ferret, and human models, we combined comparative transcriptomics with mathematical modelling to identify conditions that scale temporal gene expression programs during neurogenesis. We show that H3K27me3-mediated repression is critical for maintaining species-specific neurogenesis timescales, and its ablation scales down neurogenesis duration. Furthermore, we identified the tricarboxylic-acid (TCA)-cycle metabolite α-ketoglutarate as a modulator of developmental timing via H3K27me3 demethylation. Together, our findings link epigenetic and metabolic states to the control of species-specific developmental timescales and, ultimately, brain size.
Hypomyelinating leukodystrophy 1 (HLD1), also known as Pelizaeus–Merzbacher disease (PMD), is a severe X-linked hereditary hypomyelinating/demyelinating disorder caused primarily by genomic duplications or multiplications that lead to the increased expression of proteolipid protein 1 (PLP1). Aberrant PLP1 expression impairs oligodendrocyte differentiation and disrupts myelin formation in the central nervous system (CNS). Despite decades of research, effective disease-modifying therapies remain unavailable. In the present study, we investigated the potential of Chinpi, the Citrus Unshiu Peel extract commonly utilized in traditional herbal medicine and reported to protect cells from various cellular stresses, using both in vitro cellular and in vivo animal models of PMD. Using an FBD-102b oligodendrocyte precursor model cell line engineered to overexpress PLP1, we demonstrated that treatment with Chinpi significantly ameliorates critical defects in morphological differentiation and successfully restores the expression of major myelin proteins. Furthermore, oral administration of Chinpi to PLP1 transgenic mice improves myelin protein expression in the brain and significantly alleviates progressive motor incoordination, as assessed by behavioral tests. Taken together, these findings suggest that Chinpi exerts protective effects against PLP1-induced morphological differentiation defects and subsequent reductions in myelin protein expression, highlighting its potential as a recovery approach for PMD.